Author: claimsbot

1. A compound represented by Formula (I):
wherein
(a) W is C1-C6 alkyl, halogen, optionally substituted aryl, optionally substituted aralkyl or optionally substituted aralkenyl;
(b) Cyc is C3 or C4 cycloalkyl;
(c) p is an integer from 0 to 4;
(d) m is 1 or 2;
(e) Y is O, S, or NR;
(f) if m is 1 and if p is 0, Y is O, and n is not 0, then Z is (cyclo)alkycarbonyl or if m is 1 and if p is 0, Y is O and n is 0, then Z is heterocycle alkyl;
(g) X is O, S, NR, or CR3R4;
(h) R is H, alkyl, aryl, or
\u2003where i is an integer from 2 to 4;
(i) Z is H, alkyl, heterocycle alkyl, cycloalkyl, aryl or optionally substituted C1-C6 alkylcarbonyl or
\u2003when X is NR and R is
\u2003or when X is NR, R and Z may be taken together with N to form a nitrogen-containing heterocyclic ring;
(j) R1 is H, alkyl or aryl;
(k) R2 is H, alkyl, aryl or \u2550O;
(l) R3 and R4 are, independently, H, alkyl or aryl; or when X is CR3R4 then R3 and R4, taken together with the carbon atom, may form a heterocyclic ring; and
(m) n is an integer from 1 to 10; or a pharmaceutically acceptable salt, ester or prodrug thereof.
2. A compound according to claim 1 wherein m is 1.
3. A compound according to claim 1, wherein p is 0.
4. A compound according to claim 3, wherein Y is O; X is NR or O; R1, R2, R3 and R4 are H; n is 1 to 4; and Z is cycloalkyl carbonyl.
5. The compound according to claim 4, wherein n is 1.
6. A compound according to claim 3, wherein Y is S.
7. A compound according to claim 3, wherein Y is NR.
8. A compound according to claim 3, wherein Y is O and n is 0.
9. A compound according to claim 8, wherein Z is heterocycle alkyl.
10. A compound according to claim 3, wherein n is 0 and Z is heterocycle alkyl.
11. A compound according to claim 1, wherein m is 2.
12. A compound according to claim 11 wherein Cyc is C3 cycloalkyl.
13. A compound according to claim 12 wherein Y is O.
14. A compound according to claim 13 wherein X is O and Z is alkyl.
15. A compound according to claim 14 wherein p is 0.
16. A compound according to claim 15 wherein R1 and R2 are H.
17. A compound according to claim 1 wherein p is 1, 2, 3 or 4.
18. A compound according to claim 17 wherein Cyc is C3 cycloalkyl.
19. A compound according to claim 18 wherein W is methyl or halogen.
20. A compound according to claim 18 wherein W is optionally substituted phenyl.
21. A compound according to claim 1 wherein m is 1 and p is 0.
22. A compound according to claim 21 wherein Y is S.
23. A compound according to claim 22 wherein R2 is \u2550O.
24. A compound according to claim 23 wherein X is O.
25. A compound according to claim 22 wherein X is NR.
26. A compound according to claim 22 wherein n is 0 and Z is heterocycle alkyl.
27. A compound according to claim 26 wherein Z is heteroarylalkyl.
28. A compound according to claim 22 which is esterfied with CoA.
29. A compound according to claim 21 wherein n is 0 and Z is heterocycle alkyl.
30. A compound of Formula (IIS)
wherein (a) W is C1-C6 alkyl, halogen, optionally substituted aryl, optionally substituted aralkyl or optionally substituted aralkenyl; (b) Cyc is C3 or C4 cycloalkyl; and (c) p is an integer from 1 to 4; or a pharmaceutically acceptable salt thereof.
31. A compound according to claim 30 wherein Cyc is C3 cycloalkyl.
32. A compound according to claim 31 wherein W is methyl or halogen.
33. A compound according to claim 32 wherein W is methyl.
34. A compound of the formula:
wherein
W is C1-C6 alkyl, halogen, or aryl;
Cyc is C3 or C4 cycloalkyl;
p is an integer from 0 to 3 when Cyc is C4 cycloalkyl, or p is an integer from 0 to 2 when Cyc is C3 cycloalkyl;
Y is NR;
X is O, S, NR, or CR3R4;
R is H, alkyl, aryl, or
where i is an integer from 2 to 4;
Z is H, alkyl, cycloalkyl, aryl or (cyclo)alkylcarbonyl or
if X is NR and R is
R1 is H, alkyl or aryl;
R2 is H, alkyl, aryl or \u2550O;
R3 and R4 are, independently, H, alkyl or aryl; and
n is an integer from 1 to 10; or a pharmaceutically acceptable salt, ester or prodrug thereof.
35. A compound according to claim 34 represented by the formula:
W is C1-C6 alkyl, halogen, or aryl;
Cyc is C3 or C4 cycloalkyl;
p is an integer from 0 to 3 when Cyc is C4 cycloalkyl, or p is an integer from 0 to 2 when Cyc is C3 cycloalkyl;
Y is NR;
X is O, S, NR, or CR3R4;
R is H, alkyl or aryl;
Z is H, alkyl, cycloalkyl, aryl or (cyclo)alkylcarbonyl;
R1 is H, alkyl or aryl;
R2 is H, alkyl, aryl or \u2550O;
R3 and R4 are, independently, H, alkyl or aryl; and
n is an integer from 1 to 10; or a pharmaceutically acceptable salt, ester or prodrug thereof.
36. The compound according to claim 35, wherein p is 0.
37. The compound according to claim 36, wherein X is NR or O;
R1 and R2 are H;
n is 1 to 4; and
Z is lower alkyl, cycloalkyl or phenyl.
38. The compound according to claim 36, wherein X is O;
R1 and R2 are H;
n is 1 or 2; and
Z is H or lower alkyl.
39. The compound according to claim 36 wherein X is O;
R1 is methyl and R2 is H;
n is 1 or 2; and
Z is H.
40. The compound according to claim 34, which is selected from the group consisting of:
(cyclobutanecarbonyl-amino)-acetic acid;
2-(cyclopropanecarbonyl-amino)-propionic acid; and
cyclopropanecarboxylic acid (2-isopropoxy-ethyl)-amide.
41. A compound of the formula:
W is C1-C6 alkyl, halogen, or aryl;
Cyc is C3 or C4 cycloalkyl;
p is an integer from 0 to 3 when Cyc is C4 cycloalkyl, or p is an integer from 0 to 2 when Cyc is C3 cycloalkyl;
Y is O, S, or NR;
X is O, S, NR, or CR3R4;
R is H, alkyl, aryl, or
where i is an integer from 2 to 4;
Z is (cyclo)alkylcarbonyl or
if X is NR and R is
R1 is H, alkyl or aryl;
R is H, alkyl, aryl or \u2550O;
R3 and R4 are, independently, H, alkyl or aryl; and
n is an integer from 1 to 10; or a pharmaceutically acceptable salt, ester or prodrug thereof.
42. A compound according to claim 41 represented by the formula:
wherein
W is C1-C6 alkyl, halogen, or aryl;
Cyc is C3 or C4 cycloalkyl;
p is an integer from 0 to 3 when Cyc is C4 cycloalkyl, or p is an integer from 0 to 2 when Cyc is C3 cycloalkyl;
Y is O, S, or NR;
X is O, S, NR, or CR3R4;
R is H, alkyl or aryl;
Z is (cyclo)alkylcarbonyl, or
R1 is H, alkyl or aryl;
R2 is H, alkyl, aryl or \u2550O;
R3 and R4 are, independently, H, alkyl or aryl; and
n is an integer from 1 to 10; or a pharmaceutically acceptable salt, ester or prodrug thereof.
43. The compound according to claim 41, wherein p is 0.
44. The compound according to claim 43, wherein Y is O;
X is NR or O;
R1, R2, R3 and R4 are H;
n is 1 to 4.
45. The compound according to claim 43, wherein Y is NR;
X is O;
R1, R2, R3 and R4 are H;
n is 1 or 2.
46. The compound according to claim 41, which is selected from the group consisting of:
cyclopropanecarboxylic acid, 2-(2-cyclopropanecarbonyloxy-ethoxy)-ethyl ester;
cyclobutanecarboxylic acid, (2-cyclobutanecarbonyloxy-ethoxy)-ethyl ester;
cyclopropanecarboxylic acid, 2-2-(2-cyclopropanecarbonyloxy-ethoxy)-ethoxy-ethyl ester;
cyclobutanecarboxylic acid, 2-2-(2-cyclobutanecarbonyloxy-ethoxy)-ethoxy-ethyl ester and
cyclopropanecarboxylic acid 2-{2-bis-(2-cyclopropanecarbonyloxy-ethyl)-amino-ethyl} (2 cyclopropanecarbonyloxy-ethyl)-amino ethyl ester.
47. A compound of the formula:
wherein
W is C1-C6 alkyl, halogen or aryl;
Cyc is C3 or C4 cycloalkyl;
p is an interger for 0 to 3 when Cyc is C4 cycloalkyl or p is an interger from 0 to 2 when Cyc is C3 cycloalkyl;
Y is O;
X is NR;
R is H, alkyl, aryl, or
where i is an integer from 2 to 4;
Z is H, alkyl, cycloalkyl, aryl or (cyclo)alkylcarbonyl or
if X is NR and R is
R1 is H, alkyl or aryl;
R2 is H, alkyl, aryl or \u2550O;
R3 and R4 are, independently, H, alkyl or aryl; and
n is an integer from 1 to 10; or a pharmaceutically acceptable salt, ester or prodrug thereof.
48. A compound according to claim 47 represented by the formula:
wherein
W is C1-C6 alkyl, halogen, or aryl;
Cyc is C3 or C4 cycloalkyl;
p is an integer from 0 to 3 when Cyc is C4 cycloalkyl, or p is an integer from 0 to 2 when Cyc is C3 cycloalkyl;
Y is O;
X is NR;
R is H, alkyl or aryl;
Z is H, alkyl, cycloalkyl, aryl or (cyclo)alkylcarbonyl;
R1 is H, alkyl or aryl;
R2 is H, alkyl, aryl or \u2550O;
R3 and R4 are, independently, H, alkyl or aryl; and
n is an integer from 1 to 10; or a pharmaceutically acceptable salt, ester or prodrug thereof.
49. The compound according to claim 47, wherein p is 0.
50. The compound according to claim 49, wherein
R1, R2, R3 and R4 are H;
n is 1 to 4; and
Z is H, lower alkyl, cycloalkyl or phenyl.
51. The compound according to claim 48, wherein R is H or lower alkyl;
R1, R2, R3 and R4 are H;
n is 1 or 2; and
Z is H or lower alkyl.
52. The compound according to claim 47, which is selected from the group consisting of:
cyclopropanecarboxylic acid 2-(2-dimethylamino-ethoxy)-ethyl ester; and
cyclobutanecarboxylic acid 2-(2-dimethylamino-ethoxy)-ethyl ester.
53. A compound of the formula:
wherein
W is aryl;
Cyc is C3 or C4 cycloalkyl;
p is 1;
Y is O, S, or NR;
X is O, S, NR, or CR3R4;
R is H, alkyl, aryl, or
where i is an integer from 2 to 4;
Z is H, alkyl, cycloalkyl, aryl or (cyclo)alkylcarbonyl or
if X is NR and R is
R1 is H, alkyl or aryl;
R2 is H, alkyl, aryl or \u2550O;
R3 and R4 are, independently, H, alkyl or aryl; and
n is an integer from 1 to 10; or a pharmaceutically acceptable salt, ester or prodrug thereof.
54. A compound according to claim 53 represented by the formula:
wherein
W is aryl;
Cyc is C3 or C4 cycloalkyl;
p is 1;
Y is O, S, or NR;
X is O, S, NR, or CR3R4;
R is H, alkyl or aryl;
Z is H, alkyl, cycloalkyl, aryl or (cyclo)alkylcarbonyl;
R1 is H, alkyl or aryl;
R2 is H, alkyl, aryl or \u2550O;
R3 and R4 are, independently, H, alkyl or aryl; and
n is an integer from 1 to 10; or a pharmaceutically acceptable salt, ester or prodrug thereof.
55. The compound according to claim 53, wherein Y is O;
X is NR or O;
R1, R2, R3 and R4 are H;
n is 1 to 4; and
Z is lower alkyl, cycloalkyl or phenyl.
56. A compound according to claim 53 wherein
X is O;
R1, R2, R3 and R4 are H;
n is 1 or 2; and
Z is H or lower alkyl.
57. The compound according to claim 53, which is selected from the group consisting of:
trans-2-phenyl-cyclopropanecarboxylic acid 2-isopropoxy ethyl ester;
trans-2-phenyl-cyclopropanecarboxylic acid 2-ethoxy-ethyl ester; and
1-phenyl-cyclopropanecarboxylic acid 2-ethoxy-ethyl ester.
58. A compound according to claim 1 which is selected from the group consisting of:
1-phenyl-cyclopropanecarboxylic acid, 2-ethoxy-ethyl ester;
1-methyl-cyclopropanecarboxylic acid, 2-ethoxy-ethyl ester;
2,2,3,3, tetramethyl-cyclopropanecarboxylic acid, 2-ethoxy-ethyl ester;
trans-2-methyl-cyclopropanecarboxylic acid, 2-ethoxy-ethyl ester;
2,2-dichloro-1-methyl-cyclopropanecarboxylic acid, 2-ethoxy-ethyl ester;
(1s, 2S)-2-phenyl-styrl-cyclopropanecarboxylic acid, 2-ethoxy-ethyl ester;
1-(4-methoxy-phenyl)-cyclopropanecarboxylic acid, 2-ethoxy-ethyl ester;
1-phenyl-cyclopropanecarboxylic acid, 2-2-(2-methoxy-ethoxy)-ethoxy-ethyl ester; and
1-(1-phenyl-1-cyclopropanecarboxylic acid)-2-(1-phenyl-cyclopropanecarbonyloxy)-ethyl ester.
59. The compound according to claim 1, cyclopropane-carboxylic acid, 2-cyclopropanecarbonyloxy-ethyl ester.
60. A compound according to claim 1 which is selected from the group consisting of:
cyclopropane-1,1-dicarboxylic acid, bis-(2-ethoxy-ethyl) ester; and
cyclopropane-1,1-dicarboxylic acid, bis-(2-methoxy-ethyl) ester.
61. A compound according to claim 1 which is selected from the group consisting of
cyclopropanecarboxylic acid, 2-(4-methyl-thiazol-5-yl)-ethyl ester;
cyclopropanecarboxylic acid-2-morpholin-4-yl-ethyl ester;
cyclopropanecarboxylic acid, 5-ethyl-1,3-dioxan-5-ylmethyl ester; and
cyclopropanecarboxylic acid, 2,3-dihydro-benzo(1,4)-dioxin-2-ylmethyl ester.
62. A compound according to claim 1 which is selected from the group consisting of
cyclopropanecarbonylsulfanyl-acetic acid methyl ester;
cyclopropanecarbothioic acid, S-(2-acetylamino-ethyl) ester; and
cyclopropanecarbothioic acid, S-furan-2-ylmethyl ester.
63. The compound 1,2,3,5,6-penta-O-(cyclopropanecarbonyl)-D-glucopyranose.
64. A pharmaceutical composition comprising a glucose utilization increasing amount of at least one compound of claim 1.
65. A pharmaceutical composition comprising a glucose utilization increasing amount of at least one compound of claim 30.
66. A pharmaceutical composition comprising a glucose utilization increasing amount of at least one compound of claim 34.
67. A pharmaceutical composition comprising a glucose utilization increasing amount of at least one compound of claim 35.
68. A pharmaceutical composition comprising a glucose utilization increasing amount of at least one compound of claim 41.
69. A pharmaceutical composition comprising a glucose utilization increasing amount of at least one compound of claim 47.
70. A pharmaceutical composition comprising a glucose utilization increasing amount of at least one compound of claim 53.
71. A method for increasing glucose utilization in a cell, tissue or organ of a warm blooded animal comprising treating said cell, tissue or organ with glucose utilization effective amount of at least one compound of claim 1.
72. A method for increasing glucose utilization in a cell, tissue or organ of a warm blooded animal comprising treating said cell, tissue or organ with glucose utilization effective amount of at least one compound of claim 30.
73. A method for increasing glucose utilization in a cell, tissue or organ of a warm blooded animal comprising treating said cell, tissue or organ with glucose utilization effective amount of at least one compound of claim 34.
74. A method for increasing glucose utilization in a cell, tissue or organ of a warm blooded animal comprising treating said cell, tissue or organ with glucose utilization effective amount of at least one compound of claim 35.
75. A method for increasing glucose utilization in a cell, tissue or organ of a warm blooded animal comprising treating said cell, tissue or organ with glucose utilization effective amount of at least one compound of claim 41.
76. A method for increasing glucose utilization in a cell, tissue or organ of a warm blooded animal comprising treating said cell, tissue or organ with glucose utilization effective amount of at least one compound of claim 47.
77. A method for increasing glucose utilization in a cell, tissue or organ of a warm blooded animal comprising treating said cell, tissue or organ with glucose utilization effective amount of at least one compound of claim 53.
78. A method according to claim 71, wherein said organ is heart.
79. A method according to claim 71, wherein said cell is a myocardial cell.
80. A method for treatment of physiological conditions or disorders treatable by increasing glucose utilization comprising:
administering to a patient in need of such treatment, effective amount to increase glucose utilization of a pharmaceutical composition comprising at least one compound of claim 1.
81. A method for treatment of physiological conditions or disorders treatable by increasing glucose utilization comprising:
administering to a patient in need of such treatment, effective amount to increase glucose utilization of a pharmaceutical composition comprising at least one compound of claim 30.
82. A method for treatment of physiological conditions or disorders treatable by increasing glucose utilization comprising:
administering to a patient in need of such treatment, effective amount to increase glucose utilization of a pharmaceutical composition comprising at least one compound of claim 34.
83. A method for treatment of physiological conditions or disorders treatable by increasing glucose utilization comprising:
administering to a patient in need of such treatment, effective amount to increase glucose utilization of a pharmaceutical composition comprising at least one compound of claim 35.
84. A method for treatment of physiological conditions or disorders treatable by increasing glucose utilization comprising:
administering to a patient in need of such treatment, effective amount to increase glucose utilization of a pharmaceutical composition comprising at least one compound of claim 41.
85. A method for treatment of physiological conditions or disorders treatable by increasing glucose utilization comprising:
administering to a patient in need of such treatment, effective amount to increase glucose utilization of a pharmaceutical composition comprising at least one compound of claim 47.
86. A method for treatment of physiological conditions or disorders treatable by increasing glucose utilization comprising:
administering to a patient in need of such treatment, effective amount to increase glucose utilization of a pharmaceutical composition comprising at least one compound of claim 53.
87. A method according to claim 80, wherein said disorder or condition is ischemicreperfusion injury, post myocardial infarction, angina, heart failure, a cardiomyopathy, peripheral vascular disease, diabetes, and lactic acidosis, or symptoms or side effects associated with open heart surgery, bypass surgery, or heart transplant.
88. A method according to claim 87, wherein said disorder or condition is ischemicreperfusion injury.
89. A kit containing a pharmaceutical composition according to claim 64.
90. A kit according to claim 89, wherein said kit comprises a label or packaging insert containing instructions for use, in vitro, in vivo, or ex vivo, of components of said kit.
91. A method for increasing glucose utilization in a cell, tissue or organ of a warm blooded animal which comprises treating said cell, tissue or organ with a glucose utilization effective amount of a compound selected from the group consisting of a prodrug of
cyclopropane thiocarbonyl CoA or a thioester of cyclopropane carbothionic acid.
92. A method for increasing glucose utilization in a cell, tissue or organ of a warm blooded animal which comprises treating said cell, tissue or organ with a glucose utilization effective amount of a compound of claim 1 which forms a CoA ester in vivo.
93. A method for increasing glucose utilization in a cell, tissue or organ of a warm blooded animal which comprises treating said cell, tissue or organ with a glucose utilization effective amount of a compound of claim 30 which forms a CoA ester in vivo.
94. A method for treatment of physiological conditions or disorders treatable by increasing glucose utilization comprising administering to a patient in need of such treatment an amount of a PDHK inhibitor effective to increase glucose utilization.
95. A method for treatment of physiological conditions or disorders treatable by increasing glucose utilization comprising administering to a patient in need of such treatment an amount of a PDHK inhibitor effective to increase glucose utilization wherein said PDHK inhibitor comprises a compound of claim 1 which forms a CoA ester in vivo.
96. A method for treatment of physiological conditions or disorders treatable by increasing glucose utilization comprising administering to a patient in need of such treatment an amount of a PDHK inhibitor effective to increase glucose utilization wherein said PDHK inhibitor comprises a compound of claim 30 which forms a CoA ester in vivo.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. An airbag module for a steering wheel of a vehicle, the module comprising:
a gas generator;
an airbag;
a covering configured to face a passenger compartment of the vehicle;
an elastic subassembly for mounting the gas generator;
wherein one end of the subassembly includes first and second retaining elements, the first retaining element extending obliquely upward toward the covering and the second retaining element extending obliquely downward away from the covering;
wherein the other end of the subassembly contacts the gas generator and an end of the retaining elements contact another part of the airbag module, and
wherein the retaining elements have a finger-shaped cross section.
2. The airbag module of claim 1, wherein the retaining elements contact a retaining plate.
3. The airbag module of claim 1, wherein the retaining elements contact a generator carrier.
4. The airbag module of claim 1, wherein the retaining elements contact a diffuser housing.
5. The airbag module of claim 1, wherein the retaining elements are fastened to the gas generator.
6. The airbag module of claim 1, wherein the first and second retaining elements are fastened to the another part of the airbag module.
7. The airbag module of claim 1, wherein the elastic subassembly includes a plurality of spaced apart elastic subassemblies.
8. The airbag module of claim 7, wherein the elastic subassemblies are evenly spaced apart.
9. The airbag module of claim 7, comprising at least three elastic subassemblies.
10. The airbag module of claim 1, wherein the elastic subassembly is annular.
11. The airbag module of claim 1, wherein the elastic subassembly has a cross-sectional Y-shape, and wherein the retaining elements comprise the obliquely running branches of the Y-shape.
12. The airbag module of claim 11, wherein the elastic subassembly is positioned in the airbag module so that a substantially vertical section of the Y-shape extends in a plane of a generator carrier or parallel to a plane of a generator carrier.
13. The airbag module of claim 1, wherein the first retaining element engages in a depression of a generator carrier, and the second retaining element engages in a depression of a retaining plate connected to the generator carrier.
14. The airbag module of claim 1, wherein the elastic subassembly is fastened to a flange connected to the gas generator.
15. The airbag module of claim 1, wherein the elastic subassembly comprises rubber or silicone.
16. The airbag module of claim 1, wherein the elastic subassembly is injection molded onto a flange connected to the gas generator.
17. The airbag module as claimed claim 1, wherein the elastic subassembly is connected to a generator carrier, and wherein the first and second retaining elements engage a recess on the gas generator.
18. The airbag module of claim 1, wherein the first retaining element is provided in an upper region of the airbag module, and wherein the second retaining element is provided in lower region of the gas generator.
19. The airbag module of claim 1, wherein the retaining elements are fastened to the gas generator, and wherein the first retaining element is arranged in an upper region of the airbag module and rests on a housing surrounding the gas generator, and wherein the second retaining element is arranged in a lower region of the gas generator and rests on a housing and on a retaining plate.
20. The airbag module of claim 1, wherein the elastic subassembly is configured to cover the gas generator.
21. An airbag module for a steering wheel of a vehicle, the module comprising:
a gas generator;
an airbag;
a covering configured to face a passenger compartment of the vehicle;
an elastic subassembly for mounting the gas generator;
wherein one end of the subassembly includes first and second retaining elements, the first retaining element extending obliquely upward toward the covering and the second retaining element extending obliquely downward away from the covering;
wherein the other end of the subassembly contacts the gas generator and an end of the retaining elements contact another part of the airbag module, and
wherein the subassembly is fastened to the gas generator.
22. An airbag module for a steering wheel of a vehicle, the module comprising:
a gas generator;
an airbag;
a covering configured to face a passenger compartment of the vehicle;
an elastic subassembly for mounting the gas generator;
wherein one end of the subassembly includes first and second retaining elements, the first retaining element extending obliquely upward toward the covering and the second retaining element extending obliquely downward away from the covering;
wherein the other end of the subassembly contacts the gas generator, and
wherein the first and second retaining elements are fastened to the another part of the airbag module.
23. An airbag module for a steering wheel of a vehicle, the module comprising:
a gas generator;
an airbag;
a covering configured to face a passenger compartment of the vehicle;
an elastic subassembly for mounting the gas generator;
wherein the subassembly includes first and second retaining elements, each retaining element having first and second ends, the first retaining element extending obliquely upward toward the covering and the second retaining element extending obliquely downward away from the covering; and
wherein the first ends of the retaining elements contact the gas generator and the second ends of the retaining elements contact another part of the airbag module,
wherein the elastic subassembly has a cross-sectional Y-shape, and wherein the retaining elements comprise the obliquely running branches of the Y-shape.
24. An airbag module for a steering wheel of a vehicle, the module comprising:
a gas generator;
an airbag;
a covering configured to face a passenger compartment of the vehicle;
an elastic subassembly for mounting the gas generator;
wherein the subassembly includes first and second retaining elements, each retaining element having first and second ends, the first retaining element extending obliquely upward toward the covering and the second retaining element extending obliquely downward away from the covering; and
wherein the first ends of the retaining elements contact the gas generator and the second ends of the retaining elements contact another part of the airbag module,
wherein the elastic subassembly is fastened to a flange connected to the gas generator.
25. An airbag module for a steering wheel of a vehicle, the module comprising:
a gas generator;
an airbag;
a covering configured to face a passenger compartment of the vehicle;
an elastic subassembly for mounting the gas generator;
wherein the subassembly includes first and second retaining elements, each retaining element having first and second ends, the first retaining element extending obliquely upward toward the covering and the second retaining element extending obliquely downward away from the covering; and
wherein the first ends of the retaining elements contact the gas generator and the second ends of the retaining elements contact another part of the airbag module,
wherein the retaining elements are fastened to the gas generator, and wherein the first retaining element is arranged in an upper region of the airbag module and rests on a housing surrounding the gas generator, and wherein the second retaining element is arranged in a lower region of the gas generator and rests on a housing and on a retaining plate.

1. A mobile device comprising:
a pair of cabinet half-bodies configuring a cabinet;
a metal coupling member for coupling the cabinet half-bodies; and
a synthetic resin cover body opened with at least two pass holes through which a strap is passed, and arranged with a strap receiving piece between the pass holes; wherein
the strap receiving piece has an inner surface reinforced by at least one part of the coupling member, and a space through which the strap from one pass hole to the other pass hole passes is formed below the coupling member.
2. The mobile device according to claim 1, wherein the coupling member is integrally formed with a convex part which upper surface is positioned at a lower surface of the strap receiving piece, a width of the convex part being formed narrower than a width of the strap receiving piece.
3. The mobile device according to claim 2, wherein a protective piece is projected from both sides of the strap receiving piece, and the convex part is at a position depressed more than the protective piece between the protective pieces.
4. The mobile device according to claim 1, wherein one cabinet half-body, the coupling member, and the cover body are co-fixed with one screw.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A method of communicating user participation status information for a communication event in a communication system comprising:
transmitting a group communication event connection request from one user of the communication system to a plurality of second users of the communication system;
detecting if at least one of said second users has established a communication event connection in response to receiving the request;
generating a notification message indicating the participation status of said at least one second user, wherein said participation status indicates if said at least one second user has established a communication event connection in response to receiving the request; and
transmitting the notification message to at least one other of said second users.
2. The method as claimed in claim 1 wherein the communication connection request is transmitted using a first protocol.
3. The method as claimed in claim 1 wherein the notification message is transmitted using a second protocol.
4. The method as claimed in claim 1 wherein the group communication event connection request is a group call set up request.
5. The method as claimed in claim 4 wherein the step of detecting if the at least one second user has established a communication event connection comprises detecting if the at least one second user has established a call connection with said first user in response to receiving the group call set up request.
6. The method as claimed in claim 1 wherein the group communication event connection request is a group file transfer request.
7. The method as claimed in claim 6 wherein the step of detecting if the at least one second user has established a communication event connection comprises detecting if the at least one second user has accepted the file transfer from the first user in response to receiving the group file transfer request.
8. The method as claimed in claim 1 wherein the notification message identifies the at least one second user.
9. The method as claimed in claim 2 wherein the first protocol is one of a calling protocol, a file transfer protocol, or a short messaging service protocol (SMS).
10. The method as claimed in claim 3 wherein the second protocol is an instant messaging protocol.
11. The method as claimed in claim 1 further comprising the steps of: receiving the notification message at a user terminal of said at least one other second user; analysing the participation status of the at least one second user indicated by the notification message; and determining if the communication event is in progress based on the participation status of the at least one second user.
12. The method as claimed in claim 11 further comprising the step of;
displaying an indicator of the participation status of the at least one second user in a user interface of a client executed at the user terminal of the at least one other second user in accordance with the indicated participation status of the at least one second user.
13. The method as claimed in claim 12 wherein the indicator of the participation status of the at least one second user indicates one of: call in progress, call not in progress, ringing, transferring file, or file transfer complete.
14. The method as claimed in claim 1 wherein the at least one other second user has not established a communication event connection in response to receiving the request.
15. A communication system comprising;
a first terminal; and
a plurality of second terminals, wherein the first terminal comprises means for transmitting a group communication event connection request to the plurality of second terminals via the communication system;
means for detecting if at least one of said second terminals has established a communication event connection in response to receiving the request;
means for generating a notification message indicating the participation status of said at least one second terminal, wherein said participation status indicates if said at least one second terminal has established a communication event connection in response to receiving the request; and
means for transmitting the notification message to at least one other of said second users.
16. The communication system as claimed in claim 15 wherein said at least one other second terminal comprises:
means for receiving the notification message;
means for analysing the participation status of the at least one second user indicated by the notification message; and
means for determining if the communication event is in progress based on the participation status of the at least one second user.
17. The communication system as claimed in claim 16 wherein said at least one other second terminal comprises:
means for displaying an indicator of the participation status of the at least one second user in accordance with the indicated participation status of the at least one second user.
18. The communication system as claimed in claim 17 wherein the indicator of the participation status of the at least one second user indicates one of: call in progress, call not in progress, ringing, transferring file, or file transfer complete.
19. A computer program product comprising program code which when executed by a computer implement the steps according to the method of claim 1.